Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

NCT05914441 · tracked via the Priya Life Science Spain tracker

Sponsor

Fundación Española de Hematología y Hemoterapía

Phase

Observational

Started

2024-03-22

Last updated

2024-05-29

Condition(s) studied

Purpura, Thrombocytopenic

Investigational drug(s) / intervention(s)

Standard clinical practice

Standard clinical practice: The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Study summary

REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.

The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Eligibility

Sex

ALL

Min age

—

Max age

99 Years

Healthy volunteers

Inclusion Criteria: 1. Patients with diagnosis of TTP according to International Consensus criteria from centres in Spain and Portugal. 2. Patients that voluntarily sign the informed consent. For subjects unable to provide informed consent, a fully recognized medical authority may be used according to local laws. 3. Patients between 0 to 99 years old at the time of diagnosis. Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study. Exclusion Criteria: 1. Inability to comply with study procedures and follow-up exams. 2. Patients with any type of alteration that compromises their ability to grant written informed consent. 3. Patients that do not consent to participate in the study and do not sign informed consent. 4. Patients that do not meet the criteria previously mentioned for TTP.

Primary outcome measure(s)

Incidence of TTP in Spain/Portugal — Throughout the study period, calculated for the 3 years of expected duration.
Number of patients diagnosed with TTP and enrolled in the registry per year
Morbidity of TTP in Spain/Portugal — Throughout the study period, calculated for the 3 years of expected duration.
Percentage of patients diagnosed with TTP and enrolled in the registry among spanish / portuguese population per year
Mortality of TTP in Spain/Portugal — Throughout the study period, calculated for the 3 years of expected duration.
Percentage of patients diagnosed with TTP and enrolled in the registry per year who died due to the disease

Trial sites (7)

Facility	City	Region	Status
Hospital Universitario Virgen del Rocío	Seville	Andalusia	Recruiting
Hospital Universitario Bellvitge	L'Hospitalet de Llobregat	Barcelona	Recruiting
Hospital Clínic Barcelona	Barcelona	Spain	Recruiting
Hospital Universitario de Guadalajara	Guadalajara	Spain	Recruiting
Hospital Universitario La Paz	Madrid	Spain	Recruiting
Hospital Virgen de la Arrixaca	Murcia	Spain	Recruiting
Hospital Clínico Universitario de Valencia	Valencia	Spain	Recruiting

More Fundación Española de Hematología y Hemoterapía trials in Spain

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura Active, not recruiting

RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia Recruiting

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05914441 on ClinicalTrials.gov ↗ ← All trials in Spain